| Recruiting | Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Comb NCT07198074 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer NCT06518564 | Panagiotis Konstantinopoulos, MD, PhD | Phase 2 |
| Recruiting | First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab NCT06502743 | Yonsei University | Phase 2 |
| Recruiting | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642 | Mayo Clinic | — |
| Recruiting | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endom NCT05997017 | Aadi Bioscience, Inc. | Phase 2 |
| Recruiting | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovaria NCT05950464 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers NCT05691504 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS NCT05554328 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Rec NCT05603910 | Aaron Wolfson | Phase 1 |
| Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumo NCT05564377 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation NCT05523440 | University of Oklahoma | Phase 2 |
| Recruiting | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial NCT05112601 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Endometrial Cancer Recurrence in Patients Taking Metformin NCT05192850 | WellSpan Health | — |
| Active Not Recruiting | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopia NCT04781088 | Floor Backes, MD | Phase 2 |
| Terminated | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer NCT04906382 | Floor Backes, MD | EARLY_Phase 1 |
| Recruiting | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer NCT04469764 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Terminated | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal NCT03924245 | Vanderbilt-Ingram Cancer Center | Phase 1 |
| Recruiting | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel a NCT03914612 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fall NCT03586661 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With NCT03508570 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial C NCT03367741 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer NCT03120624 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Re NCT03008408 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometri NCT01943058 | University of Southern California | Phase 2 |
| Completed | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer NCT01652794 | Case Comprehensive Cancer Center | Phase 1 |
| Completed | Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer NCT01764789 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanc NCT01198184 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignan NCT01079832 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00723255 | National Cancer Institute (NCI) | Phase 2 |
| Completed | VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00462826 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors NCT00408655 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00301964 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00095979 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00096447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patie NCT02093546 | M.D. Anderson Cancer Center | — |
| Completed | Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer NCT00072176 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Rec NCT01689714 | Endocyte | Phase 2 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors NCT00028535 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer NCT00025467 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |